Bimekizumab in Plaque Psoriasis

Launched by ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · Mar 21, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a medication called bimekizumab to see how well it works and how safe it is for people with moderate-to-severe plaque psoriasis who haven't had success with other treatments. Bimekizumab works by lowering certain substances in the body that cause inflammation, helping to reduce the symptoms of psoriasis. The trial is open to adults aged 18 and older who have tried other treatments targeting specific inflammation-related proteins but didn't achieve satisfactory results.

To participate, individuals need to have a certain level of skin involvement from psoriasis and must have stopped their last treatment with similar drugs at least four weeks prior to joining the study. Participants can expect to visit the study site for assessments and receive the study medication, while being closely monitored for any side effects. It's important to know that people with certain health conditions or recent infections may not qualify for this trial, ensuring the safety and well-being of all participants.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • Male or female participant at least 18 years of age
• • Participant is able to provide written informed consent and comply with the requirements of this study protocol.
• • Participant has a BSA score of \>3 prior to randomization.
• • Participant has previously failed treatment with an IL-17or IL-23 agent, defined as previous treatment with either drug for at least 3 months without achieving a BSA ≤3.
• • Participant's last dose with most recent IL-17 or IL-23 agent was at least 28 days prior to baseline visit.
• • Participant who are women of childbearing potential (WOCBP) must have a negative urine pregnancy test at screening and must be practicing an adequate and medically acceptable method of birth control for at least 30 days prior to Day 0 and at least 6 months after the last dose of study. Acceptable methods of birth control include intrauterine device (IUD) oral, transdermal, implanted or injected hormonal contraceptives (must have been initiated at least 1 month before entering the study); tubal ligation; abstinence; barrier methods with spermicide. If not of child-bearing potential, participants must have a sterile or vasectomized partner; have had a hysterectomy, a bilateral oophorectomy or be clinically diagnosed infertile; or be in a menopausal state for at least a year.
• • Tuberculin purified protein derivative (PPD) or QuantiFERON TB-Gold test (QFT) negative at the time of screening, or if participant has a history of positive PPD or QuantiFERON, he/she has initiated or completed the appropriate treatment for latent tuberculosis.
• • Participant is judged to be in good general health as determined by the principal investigator.
• Exclusion criteria:
• • Have predominantly pustular, erythrodermic, and/or guttate forms of psoriasis.
• • Have drug induced psoriasis
• • History of an ongoing, chronic or recurrent infectious disease, or evidence of tuberculosis infection as defined by a positive tuberculin purified protein derivative (PPD) or QuantiFERON TB-Gold test (QFT) at Screening. Participant with a positive or indeterminate PPD or QFT test must be assessed for evidence of active TB versus latent TB within 12 weeks prior to Baseline, including signs and symptoms and chest x-ray. If presence of latent tuberculosis is established, then treatment must have been initiated at least for 4 weeks prior to Baseline and completed. Participant with evidence of active TB may not be enrolled.
• • Participants with a history of HIV, or history of hepatitis C or B infections.
• • Use of any of the following therapies within 4 weeks prior to Baseline (Visit 2): systemic non-biologic psoriasis therapies, including, but not limited to: psoralens (topical or oral) and ultraviolet A (PUVA) therapy, cyclosporine, methotrexate, azathioprine, corticosteroids, apremilast, any JAK or TYK2 Inhibitors, oral retinoids, mycophenolate mofetil, sirolimus, 1, 25 dihydroxyvitamin D analogs, and other forms of phototherapy (including UVB or self-treatment with tanning beds or therapeutic sunbathing).
• • Use of topical corticosteroids, topical calcineurin inhibitors, or other topical preparations with immunomodulatory properties within 2 weeks prior to Baseline (Visit 2).
• • Use of any investigational drug or any systemic drug for psoriasis within 4 weeks prior to Baseline (Visit 2).
• • Serious concomitant illness that could require the use of systemic corticosteroids or otherwise interfere with the participant's participation in the trial.
• • Myocardial infarction or stroke within the 6 months prior to Baseline (Visit 2).
• • Clinically important deviation as judged by the investigator (such WBC\< 3) from normal limits in physical examination, vital sign measurements, clinical laboratory tests results, and not associated with a chronic, well-controlled medical condition.
• • Administration of any live vaccines 3 months prior to Baseline (Visit 2) and during the study.
• • Have a current or history of lymphoproliferative disease within 5 years prior to Baseline (Visit 2); or have current or history of any malignant disease within 5 years prior to Baseline (Visit 2).
• • History of suicide attempt, or are clinically judged by investigator to be at risk of suicide.
• • History of IBD.
• • Acute liver failure/cirrhosis.
• • Had a serious infection, been hospitalized, or received IV antibiotics for an infection, within 12 weeks prior to Baseline (Visit 2).
• • Known immunodeficiency, or history of infection typical of an immunocompromised host.